Optimistic Buy Rating for Nurix Therapeutics’ NX-5948 Driven by Strong Efficacy in CLL and Strategic Expansion Plans

TIPRANKS12-10

Analyst Gil Blum from Needham reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) and keeping the price target at $29.00. Gil Bl...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490963970?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490963970","market":"fut","top_or_hot":-1,"title":"Optimistic Buy Rating for Nurix Therapeutics’ NX-5948 Driven by Strong Efficacy in CLL and Strategic Expansion Plans","media":"TIPRANKS","content":"<div>\n<p>Analyst Gil Blum from Needham reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) and keeping the price target at $29.00. Gil Bl...</p>\n\n<a href=\"https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-nurix-therapeutics-nx-5948-driven-by-strong-efficacy-in-cll-and-strategic-expansion-plans?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Optimistic Buy Rating for Nurix Therapeutics’ NX-5948 Driven by Strong Efficacy in CLL and Strategic Expansion Plans</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOptimistic Buy Rating for Nurix Therapeutics’ NX-5948 Driven by Strong Efficacy in CLL and Strategic Expansion Plans\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 19:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-nurix-therapeutics-nx-5948-driven-by-strong-efficacy-in-cll-and-strategic-expansion-plans?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Analyst Gil Blum from Needham reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) and keeping the price target at $29.00. Gil Bl...</p>\n\n<a href=\"https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-nurix-therapeutics-nx-5948-driven-by-strong-efficacy-in-cll-and-strategic-expansion-plans?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NX","symbol_name":"Quanex Building Products","start_time":0,"source_url":"https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-nurix-therapeutics-nx-5948-driven-by-strong-efficacy-in-cll-and-strategic-expansion-plans?utm_source=itigerup.com&utm_medium=referral","article_id":"2490963970","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-nurix-therapeutics-nx-5948-driven-by-strong-efficacy-in-cll-and-strategic-expansion-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2490963970","pubTimestamp":1733829343,"columns":[],"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"Analyst Gil Blum from Needham reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) and keeping the price target at $29.00. Gil Bl...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"NX":"Quanex Building Products","NRIX":"Nurix Therapeutics"},"translate_title":"由于CLL的强大疗效和战略扩张计划，Nurix Therapeutics的NX-5948获得乐观买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRIX":1,"NX":1},"content_text":"Analyst Gil Blum from Needham reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) and keeping the price target at $29.00. Gil Bl...","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490963970"}